Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) CEO Cedric Francois sold 2,824 shares of Apellis Pharmaceuticals stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total value of $83,364.48. Following the sale, the chief executive officer now owns 415,695 shares in the company, valued at $12,271,316.40. This trade represents a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.
Cedric Francois also recently made the following trade(s):
- On Wednesday, January 22nd, Cedric Francois sold 13,551 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $30.43, for a total value of $412,356.93.
- On Friday, January 17th, Cedric Francois sold 6,007 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total value of $179,969.72.
- On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total value of $179,288.90.
Apellis Pharmaceuticals Stock Up 3.3 %
APLS traded up $0.99 during trading on Thursday, hitting $30.46. 232,907 shares of the company’s stock traded hands, compared to its average volume of 1,954,741. The company’s 50 day simple moving average is $32.20 and its two-hundred day simple moving average is $32.96. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 12-month low of $24.34 and a 12-month high of $71.90. The stock has a market capitalization of $3.79 billion, a price-to-earnings ratio of -14.99 and a beta of 0.94.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the company. William Blair assumed coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They issued an “outperform” rating on the stock. The Goldman Sachs Group lowered Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective on the stock. in a research note on Tuesday, December 17th. Needham & Company LLC decreased their price objective on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday, January 14th. Finally, Robert W. Baird reduced their target price on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Eight investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $46.71.
Read Our Latest Stock Report on Apellis Pharmaceuticals
Hedge Funds Weigh In On Apellis Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of the company. Wolverine Asset Management LLC bought a new position in Apellis Pharmaceuticals in the 3rd quarter worth $27,000. True Wealth Design LLC bought a new stake in Apellis Pharmaceuticals during the third quarter valued at about $27,000. Capital Performance Advisors LLP bought a new stake in Apellis Pharmaceuticals during the third quarter valued at about $56,000. KBC Group NV raised its holdings in Apellis Pharmaceuticals by 34.8% during the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after acquiring an additional 679 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Apellis Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after acquiring an additional 781 shares during the period. 96.29% of the stock is currently owned by hedge funds and other institutional investors.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
See Also
- Five stocks we like better than Apellis Pharmaceuticals
- How to Evaluate a Stock Before BuyingÂ
- How Value Investors Find Undervalued Stocks and Build Wealth
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Is Tonix Pharmaceuticals the Next Biotech Breakout?
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- DeepSeek Dip: Is the Nuclear Energy Sell-Off a Buying Opportunity
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.